Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C33H29F2N5O4S |
| Molecular Weight | 629.676 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(OC4=CC=C(NC(=O)C5(CC5)C(=O)NC6=CC=C(F)C=C6)C=C4F)=C3S2
InChI
InChIKey=WLAVZAAODLTUSW-UHFFFAOYSA-N
InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42)
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1967
Created by
admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023
|
||
|
NCI_THESAURUS |
C1742
Created by
admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CWG62Q1VTB
Created by
admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023
|
PRIMARY | |||
|
1123837-84-2
Created by
admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023
|
PRIMARY | |||
|
DTXSID801100124
Created by
admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023
|
PRIMARY | |||
|
SITRAVATINIB
Created by
admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023
|
PRIMARY | MedKoo CAT NO: 206510; CAS NO: 1123837-84-2; Description: Sitravatinib, also known as MGCD516 or MG516, is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth. MGCD516 treatment resulted in significant blockade of phosphorylation of potential driver RTKs and induced potent anti-proliferative effects in vitro. MGCD516 treatment of tumor xenografts in vivo resulted in significant suppression of tumor growth. (last updated: 12/28/2015). | ||
|
C117734
Created by
admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023
|
PRIMARY | |||
|
10216
Created by
admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023
|
PRIMARY | |||
|
Sitravatinib
Created by
admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023
|
PRIMARY | |||
|
DB15036
Created by
admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023
|
PRIMARY | |||
|
25212148
Created by
admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023
|
PRIMARY | |||
|
DE-140
Created by
admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023
|
PRIMARY | |||
|
100000172780
Created by
admin on Sat Dec 16 10:07:46 UTC 2023 , Edited by admin on Sat Dec 16 10:07:46 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
